文拉法辛
CYP2D6型
CYP2C19型
药代动力学
基因型
活性代谢物
药理学
内科学
细胞色素P450
CYP2C9
药物遗传学
内分泌学
代谢物
化学
生物
医学
新陈代谢
生物化学
基因
抗抑郁药
海马体
作者
Donald E. McAlpine,Joanna M. Biernacka,David A. Mrazek,Dennis J. O’Kane,Susanna R. Stevens,Loralie J. Langman,Vicki L. Courson,Jyoti Bhagia,Thomas P. Moyer
标识
DOI:10.1097/ftd.0b013e3181fcf94d
摘要
This study examines the relationship between blood concentrations of venlafaxine and its active metabolite, O-desmethyl venlafaxine (ODV), and genetic variants of the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human subjects. Trough blood concentrations were measured at steady state in patients treated with venlafaxine extended release in a clinical practice setting. CYP2D6 and CYP2C19 genotypes were converted to activity scores based on known activity levels of the two alleles comprising a genotype. After adjusting for drug dose and gender effects, higher CYP2D6 and CYP2C19 activity scores were significantly associated with lower venlafaxine concentrations (P < 0.001 for each). Only CYP2D6 was associated with the concentration of ODV (P < 0.001), in which genotypes with more active alleles were associated with higher ODV concentrations. The sum of venlafaxine plus ODV concentration showed the same pattern as venlafaxine concentrations with CYP2D6 and CYP2C19 genotypes with higher activity scores being associated with a lower venlafaxine plus ODV concentration (2D6 P = 0.01; 2C19 P < 0.001). Because allelic variants in both CYP2D6 and CYP2C19 influence the total concentration of the active compounds venlafaxine and ODV, both CYP2D6 and CYP2C19 genotypes should be considered when using pharmacogenomic information for venlafaxine dose alterations.
科研通智能强力驱动
Strongly Powered by AbleSci AI